FY2025 EPS Estimates for Chemours Cut by Zacks Research

The Chemours Company (NYSE:CC) – Zacks Research decreased their FY2025 earnings per share (EPS) estimates for Chemours in a report released on Wednesday, November 19th. Zacks Research analyst Team now forecasts that the specialty chemicals company will earn $0.92 per share for the year, down from their previous forecast of $1.30. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Chemours’ current full-year earnings is $2.03 per share. Zacks Research also issued estimates for Chemours’ Q4 2025 earnings at $0.01 EPS, Q1 2026 earnings at $0.20 EPS, Q3 2026 earnings at $0.57 EPS, FY2026 earnings at $1.74 EPS, Q2 2027 earnings at $0.66 EPS, Q3 2027 earnings at $0.70 EPS and FY2027 earnings at $2.30 EPS.

Chemours (NYSE:CC) last announced its quarterly earnings data on Thursday, November 6th. The specialty chemicals company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.04). Chemours had a negative net margin of 5.70% and a positive return on equity of 35.27%. The firm had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.50 billion. During the same period in the prior year, the firm posted $0.40 earnings per share. The business’s quarterly revenue was down .9% compared to the same quarter last year. Chemours has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS.

A number of other equities research analysts have also weighed in on CC. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Chemours in a report on Wednesday, October 8th. Royal Bank Of Canada reduced their price target on Chemours from $19.00 to $17.00 and set an “outperform” rating for the company in a report on Monday, November 10th. Truist Financial dropped their price objective on Chemours from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Mizuho cut their price objective on Chemours from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Thursday, October 16th. Finally, UBS Group decreased their target price on shares of Chemours from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, November 11th. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Chemours has an average rating of “Hold” and an average target price of $17.50.

Chemours Trading Down 2.2%

Shares of Chemours stock opened at $10.47 on Friday. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -4.71 and a beta of 1.64. Chemours has a 52-week low of $9.13 and a 52-week high of $22.38. The company’s 50-day simple moving average is $14.14 and its 200-day simple moving average is $13.19. The company has a quick ratio of 0.88, a current ratio of 1.71 and a debt-to-equity ratio of 13.66.

Institutional Trading of Chemours

Institutional investors and hedge funds have recently made changes to their positions in the stock. Amalgamated Bank increased its position in Chemours by 1.7% during the 3rd quarter. Amalgamated Bank now owns 43,528 shares of the specialty chemicals company’s stock worth $689,000 after purchasing an additional 740 shares in the last quarter. Yousif Capital Management LLC lifted its holdings in Chemours by 1.6% in the 2nd quarter. Yousif Capital Management LLC now owns 62,386 shares of the specialty chemicals company’s stock valued at $714,000 after purchasing an additional 968 shares in the last quarter. Man Group plc boosted its stake in shares of Chemours by 0.4% during the 2nd quarter. Man Group plc now owns 271,108 shares of the specialty chemicals company’s stock worth $3,104,000 after purchasing an additional 979 shares during the last quarter. CWM LLC grew its holdings in shares of Chemours by 34.7% during the second quarter. CWM LLC now owns 4,290 shares of the specialty chemicals company’s stock worth $49,000 after buying an additional 1,104 shares in the last quarter. Finally, Inspire Investing LLC raised its position in shares of Chemours by 5.7% in the first quarter. Inspire Investing LLC now owns 25,156 shares of the specialty chemicals company’s stock valued at $340,000 after buying an additional 1,357 shares during the last quarter. 76.26% of the stock is currently owned by hedge funds and other institutional investors.

Chemours Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 15th. Shareholders of record on Friday, November 14th will be given a dividend of $0.0875 per share. The ex-dividend date of this dividend is Friday, November 14th. This represents a $0.35 annualized dividend and a yield of 3.3%. Chemours’s dividend payout ratio (DPR) is presently -15.77%.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.